@article {Scuccimarrijrheum.200369, author = {Rosie Scuccimarri and Evelyn Sutton and Mary-Ann Fitzcharles}, title = {Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic}, elocation-id = {jrheum.200369}, year = {2020}, doi = {10.3899/jrheum.200369}, publisher = {The Journal of Rheumatology}, abstract = {Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/early/2020/04/01/jrheum.200369}, eprint = {https://www.jrheum.org/content/early/2020/04/01/jrheum.200369.full.pdf}, journal = {The Journal of Rheumatology} }